N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gas-chromatography-mass spectrometry by Jasperse, Bas et al.
Bas Jasperse
Cornelis Jakobs
M. Judith Eikelenboom
Christine D. Dijkstra
Bernard M.J. Uitdehaag
Frederik Barkhof
Chris H. Polman
Charlotte E. Teunissen
N-acetylaspartic acid in cerebrospinal fluid
of multiple sclerosis patients determined
by gas-chromatography-mass
spectrometry
Received: 28 February 2006
Received in revised form: 11 July 2006
Accepted: 25 July 2006
Published online: 6 April 2007
j Abstract Background Axonal
degeneration is considered to play
a major role in the development of
clinical disability in multiple scle-
rosis (MS). N-AcetylAspartic Acid
(NAA) is a neuron-speciﬁc marker
constantly identiﬁed in MR-spec-
troscopy studies of the normal and
MS brain. To our knowledge there
are no studies available that eval-
uated NAA in cerebrospinal ﬂuid
(CSF) as a possible marker for
disease severity. Objective To
evaluate CSF concentrations of
NAA in MS in relation to disease
phenotype, clinical measures of
disability and MRI markers of
disease burden. Methods NAA
concentrations were determined in
CSF of 46 patients with MS (26
relapsing remitting (RRMS), 12
secondary progressive (SPMS) and
8 primary progressive (PPMS)).
Prior to lumbar puncture, MS-
patients underwent MRI and clin-
ical examination, including the
Expanded Disability Status Scale
(EDSS) and the MS Functional
Composite (MSFC). Additionally,
CSF concentrations of NAA were
determined in 12 patients with
other neurological diseases
(OND). Results Median CSF NAA
concentration was 0.74 (IQR: 0.59–
0.94) in RRMS , 0.54 (IQR: 0.35–
0.73) in SPMS and 0.83 lmol/l
(IQR: 0.56–1.03) in PPMS patients.
SPMS patients had a signiﬁcantly
lower NAA concentration than
RRMS patients. NAA concentra-
tions correlated with EDSS
(r = )0.37, p = 0.016), MSFC
(r = 0.41, p = 0.010), normalised
brain volume (r = 0.49,
p = 0.001), T2 lesion load
(r = )0.35, p = 0.021) and black
hole lesion load (r = )0.47,
p = 0.002). No differences were
observed between OND (median:
0.57 IQR: 0.28–0.73) and MS
patients. Conclusions CSF NAA
concentration in MS patients is
related to clinical performance
and MRI measures of disease
burden and may therefore be an
important neuron speciﬁc marker
of disease severity and possibly
progression.
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Axonal damage and axonal loss are important fea-
tures of the pathology of multiple sclerosis (MS),
occurring early in the disease course and associated
with active inﬂammatory lesions [2, 13, 17, 26]. Ax-
onal degeneration is not restricted to lesions but is
also present in the normal appearing white matter
(NAWM), probably due to Wallerian degeneration
[12]. The current view is that axonal degeneration
plays a major role in the development of persisting
disability in MS [27].
A proposed in vivo marker for axonal pathology in
MS is N-AcetylAspartic Acid (NAA). NAA is an amino
acid synthesized and almost exclusively localised in
neurons [3]. Evidence from various studies suggests
that NAA is turned over more than once each day by
an intercompartimental metabolic cycle between
neurons, extracellular ﬂuid and oligodendrocytes [1].
Post-mortem investigation of spinal cords from MS
patients has shown that lower tissue concentrations of
NAA are related to lower axonal volume. Further-
more, the average NAA concentration per axonal
volume may decrease with increasing demyelination
and functional impairment of neurons [4]. MR-spec-
troscopy (MRS) is widely used to determine paren-
chymal NAA concentrations in vivo. Several MRS-
studies have shown a decrease of NAA in MS lesions
[7]. Other studies have shown that NAA decrease in
lesions and NAWM is related to clinical disability and
progressive brain atrophy [10, 9, 11] Some, but not
all, studies have shown a decrease of NAA in the
NAWM [8, 14, 28, 29]. These ﬁndings indicate that
NAA is a neuron-speciﬁc marker that reﬂects MS-
pathology related to clinical functioning. NAA may
therefore be a useful biomarker for disease progres-
sion in MS.
Methods for measuring NAA in body ﬂuids have
been developed for the diagnosis of Canavans’ dis-
ease [15]. To our knowledge, there are no studies on
NAA-concentrations in cerebrospinal ﬂuid (CSF) of
MS patients [24]. The aim of this exploratory study
was to evaluate CSF concentrations of NAA in MS-
patients in relation to disease phenotype, clinical
measures of disability and MRI markers of disease
burden.
Materials and methods
j Study population
This study is part of an ongoing research project on CSF in MS.
Patients were recruited either in response to an appeal in the
periodical of the Dutch MS society, or from patients visiting or
admitted at our clinic. Patients were requested to voluntarily un-
dergo a lumbar puncture, MRI and clinical testing. All participants
gave written informed consent and the local ethics committee ap-
proved the study.
CSF samples were collected from a group of 46 MS patients
diagnosed according to the Poser criteria [22]. Patients were clas-
siﬁed as having a relapsing remitting (RRMS, n = 26), secondary
progressive (SPMS, n = 12) or primary progressive (PPMS, n = 8)
disease course according to Lublin and Reingold [19]. Prior to
lumbar puncture patients underwent clinical examination, includ-
ing the Expanded Disability Status Scale (EDSS) and the Multiple
Sclerosis Functional Composite (MSFC) [6, 18].
The EDSS was performed by trained medical doctors, as were
the individual components of the MSFC (25-foot Timed Walk Test
(TWT), Nine-Hole Peg Test (9-HPT) and the 3 second Paced
Auditory Serial Addition Test (PASAT3)). 43 patients underwent
EDSS-examination and 39 patients underwent MSFC-examination.
The overall MSFC-score was calculated using a previously pub-
lished reference population of MS-patients [16]. MRI examination
was performed within 23 days of lumbar puncture.
Additionally, CSF was collected from 12 patients presenting
with neurological signs and symptoms that warranted a diagnostic
lumbar puncture. These patients will from now on be referred to as
 Other Neurological Diseases’ (OND). In 10 of the OND patients,
neurological disease was conﬁrmed or remained suspect on further
diagnostic testing.
j CSF-analysis
After collection, CSF samples were centrifuged, aliquoted, coded
and stored at )80  C. All CSF-samples were analysed in a single
session.
NAA was measured using a modiﬁed stable isotope dilution Gas
Chromatography-Mass Spectrometry (GC-MS) method [15]. In
short, 1 nmol [D3]-NAA was added as internal standard to 100 llo f
CSF. This was also added to an aqueous standard, to obtain a
calibration curve in the range from 0.1 to 2.0 nmol. The samples
were acidiﬁed with 30 ll HCL (6 mol/l) to pH < 2 and saturated
with NaCl. Thereafter the sample was extracted four times with 2 ml
of an ethylacetate-2-propanol mixture (v/v 10:1). The collected
organic fractions were dried by anhydrous Na2SO4 and subse-
quently evaporated to dryness at 40 C under a gentle stream of N2.
NAA was converted to its di-isopropyl derivative by adding 500 ll
isopropanol and 10 ll 6 mol/l HCl and subsequent heating for 1
hour at 120 C. An aliquot of 1 ll of this mixture was analysed by
GC-MS. GC-MS analysis of 1 ll of this mixture was performed on
an Automass II (ThermoFinnigan) system. The gas chromato-
graphic separation was achieved on a CPSil-88 capillary fused silica
column (25 m · 0.25 mm, df = 0.28 lm (Chrompack Int., Mid-
delburg, The Netherlands)), which was directly inserted into the
source of the spectrometer. Helium was used as carrier gas with a
linear ﬂow of 20 cm/s. The oven temperature was kept at 80 C for
1 min and then raised to 240 C at a rate of 30 C/min. The interface
and source temperatures were kept at 240 C. Mass fragmentogra-
phy was achieved with positive chemical ionisation with ammonia
as reagent gas at optimised source pressure. The ions m/z 260 (base
peak protonated pseudomolecular ion (M + 1) for NAA-di-iso-
propyl) and m/z 263 (internal standard [D3]-NAA-di-isopropyl)
were monitored. The inter-assay variation for this method was 8%
(n = 5) and the intra-assay variation was 2% (n = 10). All samples
were analysed within the linear range of the standard curve (0–
20 nmol/L).
The concentration of Growth-associated protein 43 (GAP43)
was measured in 44 of the 46 CSF samples from MS patients. The
results and measurement methods of GAP-43 are described else-
where [25].
632j MRI acquisition and analysis
MRI-acquisition was performed at 1.0 Tesla (Siemens, Erlangen,
Germany) and consisted of axial pre- and post-contrast T1-
weighted (repetition time [TR] = 700 ms, echo time [TE] = 15 ms,
5.5 mm slice thickness) images and T2-weighted ([TR] = 2700 ms,
[TE] = 90 ms, 5.5 mm slice thickness) images. MRI was performed
within 23 days of CSF collection. Two patients refused to undergo
MRI.
T1 hypo intense or black hole lesion load (BHLL), T2 lesion
load (T2LL) and gadolinium enhancing lesion load (GADLL)
were quantiﬁed using home-developed semi-automated seed
growing software based on a local thresholding technique pre-
sence of sadolinium enhancing lesions was noted.
Normalised brain volume (NBV) was measured on T1-weighted
pre-contrast images using Structural Image Evaluation, using
Normalisation of Atrophy Cross-sectionally (SIENAX) [23]. A de-
tailed description of SIENAX can be found in the original pre-
senting paper [23]. Two patients were excluded from brain volume
analysis, because pre-contrast MRI seans were not available. SIE-
NAX is freely available as part of the FMRIB Software Library
(www.fmrib.ox.ac.uk/fsl).
j Statistical analysis
All values are given as medians with interquartile range (IQR).
Normality of the distribution of all variables was checked. When
normality was rejected, non-parametric statistics were used. Group
comparisons for patient characteristics and study variables were
performed between MS-subtypes, all MS patients and OND, MS
subtypes and OND, patients on disease modifying therapy or not
and patients with or without contrast enhancing lesions. Generally,
p-values smaller than 0.05 were considered statistically signiﬁcant.
Comparisons between two groups were performed using the Mann-
Whitney U test or the independent samples t-test, as appropriate.
Comparisons between more than 2 groups were performed using
the Kruskal-Wallis test. When this test was signiﬁcant, subsequent
pairwise comparisons were done using Mann-Whitney U tests.
Correction for multiple comparisons in these post-hoc tests was
accomplished by setting the cut-off p-value for statistical signiﬁ-
cance at 0.05 divided by the number of comparisons. Correlation
analysis was performed using either Pearson or Spearman corre-
lations, as appropriate.
Correlations of NAA concentrations in CSF with clinical
(EDSS, MSFC), radiological measures (NBV, T2LL, BHLL) and
GAP43 concentrations in CSF were performed in the total group
of MS-patients and subgroups deﬁned by disease onset. Thus, the
relapse onset subgroup consisted of RRMS- and SPMS-patients,
and the progressive onset subgroup of PPMS-patients. All statis-
tical analyses were performed using SPSS (version 11.0) statistical
software.
Results
j Patient characteristics
Differences in patient characteristics (Table 1) be-
tween subtypes of MS were as expected. For RRMS
and SPMS patients, median time between start date of
last relapse and CSF-collection was 13.5 months (IQR:
3.8–41 months), with a minimum of 11 days. Patients
did not receive intravenous methylprednisolone for at
least 3 months prior to CSF collection. 14 MS patients
were on disease modifying therapy at the time of CSF-
collection.
j NAA concentrations in MS patients
The median CSF concentrations of NAA in MS pa-
tients are given in Figure 1.
Between MS subtypes, a signiﬁcant difference in
NAA concentration was observed (p = 0.043). Further
analysis revealed that NAA concentration was lower
Table 1 Patient characteristics
Variables Total MS n = 46 RR n = 26 SP n = 12 PP n = 8 OND n = 12
Age (Years) 45.9 (40.8–52.6) 43.5 (34.8–50.7) 49.6 (46.0–53.1) 52.2 (45.3–54.8) 46.9 (39.3–52.1)
Disease Duration (Years) 10.9 (4.2–18.9) 6.4 (3.7–14.0) 21.2 (10.9–26.0) 12.4 (3.9–19.8) NA
Male/female (n) 21/25 9/17 7/5 5/3 NA
EDSS 4.0 (3.0–5.5) 3.0 (2.5–4.0) 5.8 (4.0–7.4) 4.0 (3.6–6.4) NA
MSFC 0.4 ()0.3–0.6) 0.6 (0.2–0.9) -0.3 ()0.9–0.4) 0.4 (0.0–0.5) NA
Median values and, between brackets, IQR for clinical characteristics of MS patients and OND. (OND = other neurological diseases) NA = not applicable
Fig. 1 Concentrations of NAA in MS-subtypes and other neurological diseases
(OND). Boxes represent values from the 25
th to the 75
th percentiles, inner lines
represent the median and whiskers show the minimum value. SP patients had
a significantly lower NAA than RRMS patients (p = 0.015), as indicated by an
asterisk(*)
633in SPMS patients compared with RRMS patients
(p = 0.015). In the total group of MS patients, NAA
concentration did not correlate with disease duration
(r = )0.18, p = 0.220) or age (r = )0.38, p = 0.801)
and did not differ between patients with or without
disease modifying therapy (p = 0.779).
j NAA concentrations in MS patients compared with
OND
NAA concentration did not differ between the OND
and the total group of MS patients (p = 0.077), nor
between OND and any of the MS subtypes (RRMS,
p = 0.033; SPMS, p = 0.932; PPMS, p = 0.082).
j Lower NAA concentration in CSF is related to worse
clinical functioning
In the total MS group, NAA concentrations corre-
lated negatively with EDSS (r = )0.37, p = 0.016)
(Figure 2) and positively with MSFC (r = 0.41,
p = 0.010), indicating that worse clinical functioning
is associated with lower NAA. The correlation of NAA
with EDSS and MSFC increased when relapse onset
patients were considered separately (r = )0.49,
p = 0.003 and r = 0.50, p = 0.004).
j Lower NAA concentration in CSF is related to lower
brain volume
NBVs are presented in Table 2. A signiﬁcant differ-
ence in NBV between MS-subtypes (p = 0.006) was
observed. SPMS patients had a signiﬁcantly lower
NBV compared with RRMS patients (p = 0.001). In
the total MS-group, NAA concentration and NBV
correlated positively (r = 0.49, p = 0.001), indicating
that lower NAA was associated with lower brain vol-
ume (Figure 3). In relapse onset patients, the corre-
lation between NAA and NBV was comparable
(r = 0.50, p = 0.002) with the total MS-group.
j Lower NAA concentration in CSF is related to
higher lesion load
Lesion loads are presented in Table 2. A signiﬁcant
difference in BHLL was observed between subtypes of
MS (p = 0.010). As expected, SPMS patients had a
higher BHLL than RRMS (p = 0.005) and tended to be
higher than PPMS patients (p = 0.016).
Fig. 2 Correlation between NAA concentrations in CSF and EDSS in MS-
patients. The regression line was fitted for all MS patients (r = 0.37, p = 0.016).
(squares: RRMS patients, triangles: SPMS patients, dots: PPMS patients)
Table 2 MRI-characteristics
Characteristics Total MS RR SP PP
NBV (cm
3) 1446 (1405–1490) 1470 (1435–1516) 1400 (1346–1435) 1465 (1424–1482)
T2LL (cm
3) 3.8 (1.5–8.5) 2.6 (1.1–8.9) 7.3 (4.4–14.8) 3.2 (1.2–6.8)
BHLL (cm
3) 0.4 (0.0–1.0) 0.2 (0.0–0.6) 1.3 (0.4–2.4) 0.1 (0.0–0.6)
Median values and, between brackets, IQR, NBV = Normalised Brain Volume,
T2LL = T2 lesion load, BHLL = black hole (T1 hypo intense) lesion load
Fig. 3 Correlation between NAA concentrations in CSF and NBV in MS-
patients. The regression line was fitted for all MS patients (r = 0.49, p = 0.001).
(squares: RRMS patients, triangles: SPMS patients, dots: PPMS patients)
634In the total MS group, the CSF concentrations of
NAA correlated negatively with T2LL (r = )0.35,
p = 0.021), indicating that higher T2LL is associated
with lower NAA in CSF. In relapse onset patients,
correlation between CSF-concentrations of NAA and
T2LL (r = )0.34, p = 0.046) was similar.
BHLL correlated with CSF concentrations of NAA
in the total group (r = )0.47, p = 0.002). This was
also observed in relapse onset patients, though of
lower magnitude (r = )0.38, p = 0.026).
10 out of 42 patients had gadolinium enhancing
lesions on MRI examination. No signiﬁcant differ-
ences in CSF concentrations of NAA were observed
between patients with or without enhancing lesions
(p = 0.248). GADLL did not correlate with CSF con-
centrations of NAA (r = )0.16, p = 0.322).
j CSF concentrations of NAA and GAP43 are related
A positive correlation was observed between con-
centrations of NAA and GAP43 in the total MS group
(r = 0.44, p = 0.003), which increased when relapse
onset patients were considered separately (r = 0.581,
p < 0.001).
Discussion
Themajorﬁndingsinthisexploratorystudyarethat,in
MS patients, lower NAA concentrations in CSF are re-
lated to a later stage of relapse onset MS, more clinical
disability, higher lesion load and lower brain volume.
Our ﬁndings on CSF NAA are in line with previous
MRS studies that showed a relationship between lower
parenchymal NAA and more clinical disability as well
as lower brain volume [9–11, 20]. We also found that
NAA in CSF is lower in patients with higher lesion
load, which is in line with the lower NAA concen-
tration in MS lesions measured by MRS [7]. These
similarities suggest that NAA in CSF reﬂects a similar
pathological process as is responsible for parenchy-
mal NAA concentrations measured by MRS.
Previous studies have shown that NAA is primarily
located in neurons, and that lower parenchymal NAA
concentration is related to reduced axonal volume in
the spinal cord [1, 4]. Axonal damage has been
associated with MS induced lesions [2, 13, 17, 26] T1
hypo intense or black hole lesions are generally
considered to represent lesions with severe tis-
sue destruction, including axonal degeneration [5, 26]
Brain volume is thought to partly reﬂect the extent of
axonal degeneration in ms although demyelination,
oedema and glial cell proliferation may inﬂuence
brain volume measurements [20]. In view of this, our
ﬁnding that reduced NAA is related to lower brain
volume and higher T2, and especially black hole, le-
sion volume indicates that NAA in CSF probably re-
ﬂects axonal degeneration.
Relatively few studies have found a correlation of
biomarkers for axonal damage with clinical disability
[24]. In this study, CSF concentrations of NAA cor-
related with EDSS and MSFC, suggesting that NAA in
CSF is a biological marker that may have clinical
relevance. The strength of the relationship between
NAA concentration in CSF and clinical measures may
seem modest, there are however factors that may have
reduced the magnitude of correlations between bio-
logical markers and clinical measures. Firstly, clinical
measures have limitations as they incompletely cover
the central nervous system and are prone to observer-
bias. Therefore, clinical measures may not detect all
relevant changes in clinical functioning resulting from
MS pathology in the central nervous system. Sec-
ondly, accumulating pathological changes of the
central nervous system may not lead to clinical dis-
ability before reaching a critical threshold. Patholog-
ical changes that are reﬂected by NAA concentrations
in CSF may therefore not be clinically apparent at the
time of CSF withdrawal.
NAA concentrations in CSF were higher in RRMS
patients compared with SPMS patients. The ﬁnding
that disease duration did not correlate with NAA,
whereas a difference was observed between RRMS
and SPMS patients, is surprising. However, disease
severity or stage is not interchangeable with disease
duration, since time to conversion to SPMS and the
time frame in which disease progression occurs
varies. A mechanistic explanation for the difference
between RRMS and SPMS, could be that NAA is
released into the CSF, possibly as a result of acute
axonal damage associated with inﬂammatory activity
in especially RRMS. From this perspective, the lower
concentration of NAA in SPMS compared with
RRMS patients may reﬂect a relative decrease in
overt inﬂammatory activity. However, we did not
observe a relationship between NAA concentration
and the occurrence of contrast enhancing lesions or
with the use of disease modifying therapy. In view of
the relationships between NAA, NBV and lesion
load, the reduced NAA concentration in SPMS
compared with RRMS patients could mean that the
decrease of NAA in CSF reﬂects the accumulation of
axonal degeneration in a later stage of MS.
For direct comparison with MS patients, we had
CSF samples available from 12 patients who under-
went a lumbar puncture for diagnostic purposes
(OND). We did not observe a signiﬁcant difference
between OND and MS patients or OND and MS
subtypes. This ﬁnding does not support or invalidates
the hypothesis that decrease of NAA reﬂects axonal
degeneration in MS. However, the OND group con-
635sisted of patients with a range of neurological signs,
symptoms and diagnoses of which the effect on NAA
concentration in CSF is not known.
GAP43 is a marker associated with growth cones,
synaptic plasticity and synaptic regeneration [21].
Recently, we showed that concentrations of GAP43
can be determined in CSF and are related to brain
volume measured on MRI [25]. The relationship we
found between NAA and GAP43, suggest that both
markers reﬂect a bond damage in the MS brain.
In conclusion, our ﬁndings suggest that NAA in
CSF may be a novel neuron-speciﬁc marker for
disease severity and possibly progression in MS. The
results of this explorative study will have to be
conﬁrmed in a second, independent and larger pa-
tient group that should also be followed longitudi-
nally.
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